Thopaz for PALs Evaluation
Persistent Air Leaks
De qué trata este estudio
El registro indica que este estudio recluta participantes. La disponibilidad puede variar por centro.
- Tipo de estudio
- Observacional
- Fase
- No aplica / no indicada
- Rango de edad
- 18 años - No especificado
- Sexo admitido
- Todos los sexos
- Voluntarios sanos
- No aceptados
- Participantes
- 20 Estimado
Estos son puntos de partida, no una decisión de elegibilidad. El equipo debe revisar todos los requisitos.
Las explicaciones y la navegación están en español. Los textos proporcionados por el registro, incluidos títulos, resúmenes y criterios, se conservan en su idioma original. Puedes pedir orientación en español a WCR.
Acerca de la investigación
Persistent air leaks (PALs) are a common postoperative complication resulting from tears in the visceral pleura or peripheral lung resections. Although highly prevalent with significant consequences, traditional assessment methods lack the capability to objectively quantify air leaks, which further complicates management, results in inconsistent decision making, and prolongs hospital stays. By incorporating the Thopaz+ system, the investigators can introduce a reliable approach to objectively quantify air leaks, potentially improving clinical outcomes.
The purpose of this protocol is to perform a pilot prospective controlled clinical trial to evaluate the utility of incorporating the Thopaz+ system and its volume quantification ability in evaluating patients with persistent air leaks (PALs) to guide treatment decisions, specifically endobronchial valves (EBVs).
In the targeted cohort, the Thopaz+ will be connected to the chest tube and the data collected will be combined with that of serial balloon occlusion testing with a Fogarty balloon to accurately localize the air leak source, and subsequently consider the correct placement of EBVs. The investigators will thereby determine whether this experimental strategy will yield a more accurate and objective assessment of air leaks, facilitating timely interventions and improved patient outcomes.
Leer la descripción completa
The investigators will conduct a prospective controlled clinical trial. The investigators' target demographic includes all adult patients with lung resection and/or non-lung resection-related PAL with ipsilateral chest tubes who were not candidates for surgical intervention or patients who refused the intervention. These patients would undergo a multidisciplinary review by thoracic surgery, interventional pulmonary and the primary care team to consider a bronchoscopic approach with endobronchial valves and possibly bronchial blood patch, which is currently considered standard of care at our institution. During this standard-of-care intervention, quantitative assessment of distal occluded airway pressures/flows in various airways, as well as quantitative assessment of air leak volume will be assessed.
In current medical practice, when EBVs are considered in the context of managing PALs, bronchoscopists may opt to either conduct complete lobar occlusion (sealing of all segments within the target lobe) or segmental occlusion (sealing only selected segments within the target lobe). The decision is usually guided by localizing the source of air leak which is usually done by monitoring the reduction of air leak on the pleural drainage device following serial inflation of a Fogarty Catheter at various locations within the endobronchial tree and monitoring change in air leak visually in the pleural drainage system.
In this trial, patients with PALs will have their chest tubes connected to the Thopaz+ system. The Thopaz+ will continuously quantify the volume of air leaks, providing real-time data for analysis.
Data from both the Thopaz+ and standard serial occlusion test with Fogarty balloon will be combined and integrated to provide a comprehensive assessment of the air leak source. The bronchoscopist will perform standard visual assessment of changes in air leak during serial balloon occlusion in order to identify the best region for endobronchial treatments; use of measurements from the Thopaz and serial balloon occlusion test will be allowed as part of clinical reasoning but are not required to be used by the treating clinician.
Continuous monitoring using the Thopaz+ system may continue post-procedure to track changes in air leak volumes and patient recovery, ensuring timely interventions and optimal patient outcomes. This integrated approach aims to provide a more accurate, objective, and efficient method of managing PALs compared to traditional techniques.
¿Quién podría participar?
La lista siguiente contiene el texto del patrocinador. Puede incluir condiciones, tratamientos previos, resultados de pruebas y otros requisitos. Aparecer en tu búsqueda no significa que califiques.
Inclusion Criteria:
- Age ≥ 18 years
- Hospitalized with a persistent air leak (PAL) lasting ≥5 days despite continuous chest tube drainage.
- Undergoing bronchoscopy as part of clinical care for PAL management.
- Able and willing to provide written informed consent
Exclusion Criteria:
- Contraindications to bronchoscopy or EBV placement.
- Pregnancy.
- Inability to tolerate general anesthesia.
Población del estudio
All study subjects will be patients who meet the inclusion criteria including a willingness to read, understand, and sign the informed consent. Recruitment of study subjects will be from the pool of admitted patients from our inpatient service. They will be recruited in a consecutive fashion from the clinical practices of the investigators from BIDMC.
Entiende la evaluación inicialTratamiento, grupos y participación
El registro puede describir tratamientos y duración sin incluir un calendario completo. Pide al equipo las visitas, procedimientos, riesgos, costos y alternativas. Mantén tu atención habitual salvo que tu médico te indique un cambio.
- Asignación
- No informado
- Enmascaramiento
- No informado
Persistent air leak quantification DIAGNOSTIC_TEST
In this trial, patients with PALs will have their chest tubes connected to the Thopaz+ system. The Thopaz+ will continuously quantify the volume of air leaks, providing real-time data for analysis.
Data from both the Thopaz+ and standard serial occlusion test with Fogarty balloon will be combined and integrated to provide a comprehensive assessment of the air leak source. The bronchoscopic will perform standard visual assessment of changes in air leak during serial balloon occlusion in order to identify the best region for endobronchial treatments; use of measurements from the Thopaz and serial balloon occlusion test will be allowed as part of clinical reasoning but are not required to be used by the treating clinician.
Qué evalúan los investigadores
Estas medidas indican qué se estudia. No prueban que un tratamiento funcione.
Medidas principales
Number of Participants with Successful Intraoperative Quantification of Air Leak Volume Using Thopaz+ Digital Drainage System
Plazo: During procedure
Feasibility will be defined by the ability to obtain continuous, interpretable quantitative air leak volume data (in mL/min) during bronchoscopic evaluation of persistent air leaks. Successful quantification is defined as capturing measurable air leak volume data during serial balloon occlusion in at least one airway segment. The outcome will be reported as the number and percentage of participants with successful measurements out of the total enrolled population.
Medidas secundarias
Percentage of patients with identifiable lobar or segmental airways responsible for PAL
Plazo: During procedure
Percentage of patients with identifiable lobar or segmental airways responsible for PAL
Maximum decrease in volume of air leak during serial balloon occlusion, as measured by Thopaz+ device
Plazo: During procedure
No informado en este registro.
Treatment success: decrease of one grade in Cerfolio classification for air leaks or removal of continuous suction from chest drain.
Plazo: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
The Cerfolio classification categorizes air leaks based on their occurrence during the respiratory cycle, with grades 1-4 indicating increasing severity. Grade 1 is a forced expiratory leak, seen during coughing; Grade 2, expiratory; Grade 3, inspiratory; and Grade 4, continuous during both inspiration and expiration
Treatment failure: no decrease in the degree of the air leak (Cerfolio classification) and the need for continuous suction for chest drain
Plazo: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
No informado en este registro.
Length of stay following EBV placement
Plazo: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
No informado en este registro.
Duration of chest tube following bronchoscopy
Plazo: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
No informado en este registro.
Change in Air Leak Severity Graded by Cerfolio Classification
Plazo: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
The Cerfolio classification categorizes air leaks based on their occurrence during the respiratory cycle, with grades 1-4 indicating increasing severity. Grade 1 is a forced expiratory leak, seen during coughing; Grade 2, expiratory; Grade 3, inspiratory; and Grade 4, continuous during both inspiration and expiration
Change in Quantitative Air Leak Volume Measured by Thopaz+ Digital Drainage System
Plazo: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
The Thopaz+ device will be used to continuously measure the volume of air leak (in mL/min) before and after bronchoscopic intervention. The outcome will report the change in air leak volume from baseline (pre-bronchoscopy) to post-bronchoscopy values.
The need for additional non-surgical intervention
Plazo: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
No informado en este registro.
The need for additional surgical intervention for PAL such as video-assisted thoracoscopic surgery with mechanical pleurodesis, blebectomy or lobectomy
Plazo: From enrollment until 8 weeks follow-up (as per standard of care for bronchoscopic treatment of PALs)
No informado en este registro.
Revisa las tablas completas y sus limitaciones en el registro oficial.
Abrir resultados oficiales ↗Centros de investigación (1)
El estado general puede diferir del estado de un centro. Confirma la disponibilidad antes de trasladarte.
1 centros
Beth Israel Deaconess Medical CenterBoston, Massachusetts, United StatesReclutando
Equipo y fechas
- Patrocinador principal
- Kai Swenson
- Inicio del estudio
- 1 ene 2026 Real
- Finalización primaria
- 1 jul 2027 Estimado
- Finalización del estudio
- 1 oct 2027 Estimado
- Primera publicación
- 6 ago 2025 Real
- Última actualización
- 10 nov 2026 Real
Contactos oficiales del estudio
Título oficial del estudio
Utility of the Thopaz+ System in Evaluating Persistent Air Leaks
Consulta a Wellness Clinical Research
Tu mensaje va a WCR, incluso si otra organización realiza este estudio. WCR puede orientarte, pero podría no realizar este estudio, tener acceso a su equipo ni poder inscribirte.
Fuente: API v2 de ClinicalTrials.gov. Patrocinadores e investigadores envían la información. La NLM no aprueba la seguridad ni la ciencia de todos los estudios registrados. Aviso del registro.
Consultado: 11 nov 2026 · Última actualización del registro: 10 nov 2026
